KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to -$50.1 million.

  • Castle Biosciences' Cash from Investing Activities fell 24.34% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.4 million, marking a year-over-year increase of 0.24%. This contributed to the annual value of -$50.1 million for FY2024, which is 209.81% down from last year.
  • Per Castle Biosciences' latest filing, its Cash from Investing Activities stood at -$50.1 million for FY2024, which was down 209.81% from -$16.2 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Cash from Investing Activities peaked at -$4.7 million during FY2020, and registered a low of -$166.5 million during FY2022.
  • In the last 3 years, Castle Biosciences' Cash from Investing Activities had a median value of -$50.1 million in 2024 and averaged -$77.6 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 1,303.90% in 2021, then skyrocketed by 90.28% in 2023.
  • Yearly analysis of 5 years shows Castle Biosciences' Cash from Investing Activities stood at -$4.7 million in 2020, then tumbled by 1,303.90% to -$66.7 million in 2021, then plummeted by 149.85% to -$166.5 million in 2022, then soared by 90.28% to -$16.2 million in 2023, then slumped by 209.81% to -$50.1 million in 2024.